Evaluation of Tigecycline Efficacy and Post-Discharge Outcomes in a Clinical Practice Population with Complicated Intra-Abdominal Infection: A Propensity Score–Matched Analysis

Joseph Solomkin,¹ C. Daniel Mullins,² Alvaro Quintana,³ Christian Eckmann,⁴ Ahmed Shelbaya,^{3,5} Frank R. Ernst,⁶ Michelle R. Krukas,⁷ and Arlene Reisman⁸

Abstract

Background: The utility of tigecycline as compared with other antibiotic therapies in the treatment of patients with complicated intra-abdominal infection (cIAI) and the short- and long-term outcomes of a large cohort of severely ill patients were examined. We provide the first published data on post-discharge events for these patients.

Methods: Retrospective data for the cIAI cohort were obtained from a large clinical database. Patients aged ≥ 18 y were selected for inclusion based on hospitalization with a relevant diagnosis code and procedure code, and guideline-compliant antimicrobial therapy. Propensity scoring was used to reduce treatment-selection bias introduced by the use of observational data. Tigecycline patients were placed into quintiles based on propensity score and were matched 1:3.

Results: The final model based on propensity score matching included 2,424 patients: Tigecycline ($n = 606$) and other antibiotic therapy ($n = 1,818$). Treatment was successful in 426 (70.3%) tigecycline-treated patients and in 1,294 (71.2%) patients receiving other antibiotics. Similar treatment success occurred across all infection sites. Among survivors, treatment failure was associated with a greater need for all-cause re-hospitalization at 30 d and 180 d. No differences in cIAI-related re-hospitalization and discharge status were observed.

Conclusions: Using propensity scores to match populations, similar outcomes were demonstrated between treatment with tigecycline and other antibiotics as expressed by treatment success, the need for re-admission, similar 30-d discharge status, and the need for re-admission at 180 d.

COMPLICATED INTRA-ABDOMINAL INFECTIONS (cIAI) with high severity are associated with poor prognosis. Cure and survival are determined by anatomic extent of disease (peritonitis vs. abscess); physiologic severity, age, and comorbidities; diagnostic delay and therapy; and inappropriate

application of other elements of care. The development of computed imaging, percutaneous abscess drainage, and minimally invasive operative procedures has substantially altered the management of these infections. These technologic advances have led to improved outcomes from

¹University of Cincinnati College of Medicine, Cincinnati, Ohio.

²Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland.

³Medicine Development Group, Pfizer Inc, Collegeville, Pennsylvania.

⁴Klinikum Peine Academic Hospital of Medical University Hannover, Peine, Germany.

⁵Columbia School of Public Health, New York, New York.

⁶Indegene TTM, Kennesaw, Georgia.

⁷Quintiles, Cambridge, Massachusetts.

⁸Global Innovative Pharma Business, Pfizer Inc, New York, New York.

Presented at the Thirty-fourth Annual Meeting of the Surgical Infection Society, Baltimore, Maryland, May 1–3, 2014.

infections caused by perforations in the gastrointestinal tract [1–3].

Tigecycline, an intravenous broad-spectrum glycylcycline antimicrobial agent, is approved for use in the United States for the treatment of cIAI as well as complicated skin and skin structure infections and community-acquired bacterial pneumonia [4]. As the product label includes a black box warning highlighting an increase in all-cause mortality rates in tigecycline-treated patients as compared with those receiving a comparator treatment based on a meta-analysis of clinical trial data, it should be noted that tigecycline use should be reserved for cases when alternative agents are not suitable [4]. The cause of the increased mortality rates has not been established.

Clinical registration trials for investigational antibiotics for cIAI typically enroll patients with moderate severity of infection and illness, particularly perforated appendicitis, with minimal anticipated morbidity, and mortality rates below 5%. Translation of phase 3 registry antibiotics trials to clinical practice has been questioned. Recently published data regarding the use of tigecycline in severely ill patients (mean Acute Physiology and Chronic Health Evaluation [APACHE] II score 16.9) showed favorable results in terms of clinical outcome [5]. Nevertheless, because of the design of the study, the interpretation of these data is hampered by the lack of a comparator.

Other surveys of cIAIs, as encountered in clinical practice, do carry substantial risk of morbidity and death. Recent broad surveys have indicated a mortality rate of 10% [6,7] with morbidity and mortality rates closely tied to sepsis syndromes and uncontrolled infection. Further, the post-discharge outcome of patients cured of cIAI has not been specifically explored. Outcomes research on other acutely infected patient groups suggests frequent re-admissions for multiple infectious and non-infectious problems [8].

To evaluate short- and long-term outcomes in a group of seriously ill patients with cIAI, we conducted a retrospective, observational study using a large clinical practice database to examine the effectiveness of tigecycline use compared with other antibiotic therapies in the treatment of patients with cIAI. This provided the opportunity to examine the utility of propensity score matching in these observational trials and the short- and long-term outcomes of a large cohort of severely ill patients.

Patients and Methods

Study design

The retrospective data for the cIAI cohort were obtained from the database maintained by the Premier, Inc. (Charlotte, NC) between January 2009 and June 2012. The database contains de-identified patient data from more than 600 non-federal acute care hospitals accounting for one in five hospital discharges in the United States. De-identified data collected included hospital discharge files, patient demographics, disease state information, and date-stamped patient-level logs of billed items, including procedures, medications, laboratory, and diagnostic and therapeutic services.

Patients aged ≥ 18 y were identified for inclusion in the analysis based on relevant *International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)* diagnosis and procedure codes indicative of cIAI

(Appendix Table 1), and treated with antibiotic therapy considered appropriate in recent guidelines [3]. Index hospitalizations for cIAI occurred during the study period with no hospitalizations for cIAI within 30 d prior to the index admission. Only the first qualified admission was included for a particular patient. Patients were grouped into cohorts according to antibiotic use—tigecycline (monotherapy or in combination) or other antibiotic therapy. Because of the similarities in gram-negative spectrum and use in cIAI, a separate cohort of patients treated with tigecycline and of patients receiving imipenem-cilastatin was also included. Antibiotic administration was to have occurred for up to 2 d before the first cIAI procedure, on the day of the first cIAI procedure (index date), and for at least 2 consecutive d immediately following the surgical procedure. The observation period included the 30 d prior to index hospitalization, index admission time period, and the 30 d and 180 d following discharge from the index hospitalization. Because of the small number of imipenem-cilastatin-treated patients, adequate propensity score matching could not be performed between tigecycline and imipenem-cilastatin patients.

Outcome definitions

The health outcome of primary interest was measured by a composite binary variable (treatment success or failure). Treatment success was defined as one of two scenarios: (1) The patient was alive for at least 30 d following the index date, if still in the hospital; (2) the patient was discharged alive within 30 d of the index date without requiring a second surgical intervention related to the cIAI. If neither of those conditions was present the case was considered a treatment failure.

Hospital length of stay (LOS) was defined as the total number of d in the hospital as an admitted patient. Intensive care unit (ICU) LOS was defined as the number of d that a patient received any treatment in the ICU, identified using charge master items for ICU room and board.

Re-admission was defined as a new admission following discharge from the index hospitalization. These were limited to patients who did not die within the prior hospital stay, and to subsequent admissions to the same facility; admissions of patients to different facilities are not identifiable in the Premier database because each hospital uses its own unique patient identifier. Complicated IAI-related re-admission was identified when the re-admission data provided evidence of cIAI as the main reason for that additional stay, whereas any re-admission regardless of reason was counted among the all-cause re-admissions.

Statistical analysis

Descriptive analysis was used to describe the characteristics of the cIAI cohort. The Charlson Comorbidity Index (CCI) was used to score the patient's health status [9]. This index provides a risk of death for subjects in longitudinal studies based on comorbid diseases. Scores were grouped as 0, 1, 2, 3, and ≥ 4 (greater scores correlate to a lower probability of survival). The 3M™ All Patient Refined™ Diagnosis Related Group (APR-DRG) Classification System was used to adjust for severity of illness (SOI) and risk of mortality (ROM) allowing for the further characterization of health status [10]. The APR-DRG system is algorithm-based and takes into consideration ICD-9 diagnosis, age, gender, discharge data,

FIG. 1. Study attrition. (cIAI=complicated intra-abdominal infection; ICD-9=*International Classification of Diseases, Ninth Revision*).

TABLE 1A. PATIENT CHARACTERISTICS PRIOR TO PROPENSITY SCORE MATCHING

Characteristic ^a	Tigecycline (n = 620)	Other antibiotic therapy (n = 23,743)	p
Mean age (SD), y	62.5 (16.0)	60.6 (16.8)	0.0614
Female	349 (56.3)	12,260 (51.6)	0.0690
White	452 (72.9)	16,654 (70.1)	0.0770
APR-DRG severity of illness ^b			
Mild (1)	1 (0.2)	133 (0.6)	<0.0001
Moderate (2)	63 (10.2)	3,949 (16.6)	
Major (3)	179 (28.9)	8,528 (35.9)	
Extreme (4)	377 (60.8)	11,133 (46.9)	
APR-DRG risk of death ^b			
Mild (1)	22 (3.5)	1,617 (6.8)	<0.0001
Moderate (2)	114 (18.4)	5,881 (24.8)	
Major (3)	171 (27.6)	7,637 (32.2)	
Extreme (4)	313 (50.5)	8,608 (36.3)	
Site of infection			
Stomach	15 (2.4)	531 (2.2)	0.7613
Appendix	11 (1.8)	699 (2.9)	0.0874
Liver	3 (0.5)	142 (0.6)	0.7151
Small intestine	169 (27.3)	6,060 (25.5)	0.3283
Large intestine	265 (42.7)	9,548 (40.2)	0.2052
Pancreas	—	2 (0.0)	0.8192
Gallbladder	33 (5.3)	2,014 (8.5)	0.0051
Other abdominal surgery ^c	227 (36.6)	8,285 (34.9)	0.3756
Vasopressor use	255 (41.1)	7,807 (32.9)	<0.0001
Mechanical ventilator use	261 (42.1)	7,341 (30.9)	<0.0001

^an (%), except for age.

^bAlgorithm-based and takes into consideration ICD-9 diagnosis, age, gender, discharge data, and d on mechanical ventilation.

^cIncludes percutaneous abdominal drainage, re-opening of recent laparotomy site, and re-closure of post-operative disruption of abdominal wall.

APR-DRG = 3M™ All Patient Refined™ Diagnosis Related Group; SD = standard deviation.

TABLE 1B. PATIENT CHARACTERISTICS FOLLOWING PROPENSITY SCORE MATCHING

Characteristic ^a	Tigecycline (n = 606)	Other antibiotic therapy (n = 1,818)	p
Mean age (SD), y	62.5 (16.0)	62.2 (16.7)	0.6988
Female	341 (56.3)	1,014 (55.8)	0.8317
White	440 (72.6)	1,318 (72.5)	0.9581
APR-DRG severity of illness ^b			
Mild (1)	1 (0.2)	1 (0.1)	0.5392
Moderate (2)	63 (10.4)	168 (9.2)	
Major (3)	178 (29.4)	508 (27.9)	
Extreme (4)	364 (60.1)	1,141 (62.8)	
APR-DRG risk of death ^b			
Mild (1)	22 (3.6)	55 (3.0)	0.6070
Moderate (2)	113 (18.6)	315 (17.3)	
Major (3)	171 (28.2)	496 (27.3)	
Extreme (4)	300 (49.5)	952 (52.4)	
Site of infection			
Stomach	15 (2.5)	46 (2.5)	0.9403
Appendix	11 (1.8)	18 (1.0)	0.1057
Liver	3 (0.5)	9 (0.5)	1.000
Small intestine	165 (27.2)	505 (27.8)	0.7932
Large intestine	261 (43.1)	779 (42.8)	0.9245
Pancreas	-	1 (0.1)	0.5636
Gallbladder	33 (5.4)	101 (5.6)	0.9183
Other abdominal surgery ^c	219 (36.1)	655 (36.0)	0.9610
Vasopressor use	244 (40.3)	777 (42.7)	0.2852
Mechanical ventilator use	250 (41.3)	774 (42.6)	0.5688

^an (%), except for age.

^bAlgorithm-based and takes into consideration ICD-9 diagnosis, age, gender, discharge data, and d on mechanical ventilation

^cIncludes percutaneous abdominal drainage, re-opening of recent laparotomy site, and re-closure of post-operative disruption of abdominal wall.

APR-DRG = 3M™ All Patient Refined™ Diagnosis Related Group; SD = standard deviation.

and d on mechanical ventilation; it was applied in this study to the index hospitalization. On the basis of this system, patients are classified into one of four categories (1=minor, 2=moderate, 3=major, 4=extreme) after the end of the hospital stay. The measures reflect the SOI or ROM during that hospital stay. The APR-DRG system clinical model has been extensively reviewed and is updated regularly [10].

Propensity scoring was used to reduce treatment-selection bias introduced by the use of observational data. Propensity

scores were generated using multivariable logistic regression. The propensity score represents a patient's probability of receiving a specific treatment, in this case tigecycline, while adjusting for observed covariates [11,12]. Parameters included in the propensity score model are listed in Appendix Table 2.

Tigecycline patients were placed into quintiles based on propensity score and were matched 1:3 using greedy matching techniques based on the propensity score within

FIG. 2. Distribution of Charlson Comorbidity Index (CCI) scores prior to propensity score matching.

each quintile to examine outcomes of tigecycline versus other antibiotic therapy [13]. Student *t*-tests and Pearson chi-squared tests were used where appropriate to evaluate the effect of treatment defined as success or failure. All analyses were performed using WinSQL (Synametrics Technologies, Inc, Plainsboro, NJ) and SAS v9.2 (SAS Institute, Inc, Cary, NC).

Ethics

No informed consent was necessary for this database analysis. The database is Health Insurance Portability and Accountability Act (HIPAA)-compliant and has been certified by a third party statistical expert to contain de-identified data. This study was exempt from institutional review board review.

Results

Of the 103,366 original patients identified by ICD-9 code, 620 were included in the tigecycline cohort and 23,743 were included in the other antibiotic therapy cohort (Fig. 1). Patient demographic characteristics were similar across treatment groups. Before propensity score matching, patients in the tigecycline-treated group were more severely ill, having greater APR-DRG SOI and ROM as well as greater use of mechanical ventilation and vasopressors (Table 1A). The CCI scores for both groups are provided in Figure 2. The mean (standard deviation [SD]) CCI score for the tigecycline and other antibiotic therapy cohorts was 2.1 (2.4) and 1.9 (2.5), respectively.

Propensity score-matched population

The final model based on propensity score matching included 2,424 patients: Tigecycline, *n*=606; other antibiotic therapy, *n*=1,818 (Table 1B). Appendix Table 3 provides a listing of antibiotics included in the other antibiotic therapy population. Following matching, no substantial differences were noted between the treatment groups. Mean (SD) LOS for the index hospitalization was similar between the treatment groups (tigecycline, 11.7 [7.8] d; other antibiotic ther-

apy, 11.1 [7.5] d; *p*=0.0838). Intensive care unit utilization and ICU LOS were also similar. An ICU stay was documented in 91.2% of tigecycline-treated patients and in 90.2% of patients receiving other antibiotics, *p*=0.5952. The mean ICU LOS was ~7 d for both groups.

Treatment was successful in 426 (70.3%) tigecycline-treated patients and in 1,294 (71.2%) patients receiving other antibiotics. Similar treatment success occurred across all infection sites. Treatment success by APR-DRG was not affected by treatment selection with similar rates of success observed in both treatment groups (Table 2). Success was also not affected by vasopressor or mechanical ventilator use.

Discharge status at 30 d is presented in Table 3. No substantial differences in discharge to home health, home or self-care, skilled nursing facility, discharge to rehab facility, or outcome recorded as "expired" were identified between the two treatment groups at 30 d post-discharge. Treatment failure was associated with a greater need for all-cause re-hospitalization at 30 d and 180 d (Fig. 3). However, no difference in cIAI-related re-hospitalization was observed. Figure 4 displays the time course for re-hospitalization. Re-admission related to cIAI was separated out from re-admission for all other causes.

Tigecycline-treated comparison with imipenem-cilastatin-treated patient population

A total of 1,313 patients were included in the analysis (tigecycline, *n*=614; imipenem-cilastatin, *n*=669). These patients were not propensity score matched because the number of patients did not permit application of the 1:3 ratio used. However, there is less evidence of a need for propensity score matching because the analysis of the matching criteria did not show substantial differences among the tigecycline and imipenem-cilastatin population in those parameters used for propensity score matching, with the exception of a greater number of females in the tigecycline cohort as well as differences in race (Appendix Table 4).

Mean LOS (SD) was similar between the treatment groups (tigecycline, 11.8 [7.9] d; imipenem-cilastatin, 11.6 [7.8] d; *p*=0.6794). Intensive care unit utilization and ICU LOS were

TABLE 2. TREATMENT SUCCESS AMONG PROPENSITY SCORE-MATCHED PATIENTS

	Tigecycline (<i>n</i> = 606) <i>n</i> / <i>N</i> (%)	Other antibiotic therapy (<i>n</i> = 1,818) <i>n</i> / <i>N</i> (%)	<i>p</i>
APR-DRG severity of illness ^a			
Mild (1)	1/ 1 (100)	1/ 1 (100)	1.0000
Moderate (2)	60/ 63 (95.2)	159/ 168 (94.6)	0.8559
Major (3)	152/178 (85.4)	445/ 508 (87.6)	0.4512
Extreme (4)	213/364 (58.5)	689/1,141 (60.4)	0.5263
APR-DRG risk of death ^a			
Mild (1)	21/ 22 (95.5)	47/ 55 (85.5)	0.2173
Moderate (2)	101/113 (89.4)	284/ 315 (90.2)	0.8134
Major (3)	142/171 (83.5)	401/ 496 (80.8)	0.5248
Extreme (4)	162/300 (54.0)	562/ 952 (59.0)	0.1237
Vasopressor/mechanical ventilator use			
Vasopressor use	135/244 (55.3)	439/ 777 (56.5)	0.7476
Mechanical ventilator use	135/250 (54.0)	438/ 774 (56.5)	0.4734

^aAlgorithm-based and takes into consideration ICD-9 diagnosis, age, gender, discharge data, and d on mechanical ventilation APR-DRG = 3M™ All Patient Refined™ Diagnosis Related Group.

TABLE 3. 30-D DISCHARGE STATUS AMONG PROPENSITY SCORE-MATCHED PATIENTS

<i>Discharge status</i>	<i>Tigecycline (n=606) n (%)</i>	<i>Other antibiotic therapy (n=1,818) n (%)</i>	<i>p^a</i>
Discharged to home health	131 (21.6)	404 (22.2)	0.1714
Discharged to home/self-care	139 (22.9)	503 (27.7)	
Discharged/transferred to SNF	88 (14.5)	243 (13.4)	
Discharged/transferred to another rehab facility	23 (3.8)	62 (3.4)	
Expired	67 (11.1)	186 (10.2)	
Left AMA	1 (0.2)	6 (0.3)	0.1714
Still hospitalized	77 (12.7)	170 (9.4)	
Other ^b	80 (13.2)	244 (13.4)	

^ap = chi-square.

^bIncludes discharges/transfers to short-term general hospitals, intermediate or long-term care facilities, or unspecified locations. AMA = against medical advice; SNF = skilled nursing facility.

also similar between the two groups. Treatment was successful in 429/614 (69.9%) tigecycline-treated patients and in 479/699 (68.5%) imipenem-cilastatin-treated patients. Similar treatment success occurred across all infection sites. Treatment success by APR-DRG was not affected by treatment selection, with similar rates of success observed in both treatment groups (Table 4; both $p > 0.05$). Success was also not affected by vasopressor or mechanical ventilator use (both $p > 0.05$).

No differences in all-cause re-hospitalization and cIAI-related re-hospitalization at 30 d and 180 d were evident between the treatment groups. Among patients who were considered treatment failures, there was a greater need for all-cause re-hospitalization at 30 d and 180 d and no difference in cIAI-related re-hospitalization for the same time periods.

Discussion

Complicated IAIs, as defined in this analysis, are common and important causes of acute morbidity and death. The risk factors identified for poor outcome from the acute infectious process have been well studied and include delay in

intervention, advanced age, comorbidity, organ dysfunction, presence of malignant disease, low albumin/poor nutritional status, degree of peritoneal involvement, inability to achieve adequate debridement or control of drainage, and SOI as measured by any of several available scoring systems [3].

An important benefit of current cIAI observational studies is that the data reflect an unselected population of patients meeting disease definitions. Although this accumulates more patients with severe disease, randomization to prevent selection bias is not possible. The prescribing of therapy is based on multiple factors, including the patient's clinical condition, age, comorbidities, geographic region, formulary guidance, and provider preference. Without adjustment for confounding factors, treatment effects are heterogeneous because of patient factors (age, comorbidities, gender, concomitant therapies), and statistical analyses can be distorted [14]. Propensity score matching provides a means to overcome selection bias and allows for determining treatment effects.

In the current study of patients with cIAI, we utilized CCI as a measure of health status combined with the APR-DRG

FIG. 3. Re-hospitalization based on treatment success among propensity score-matched patients. (cIAI = complicated intra-abdominal infection).

FIG. 4. Time to re-admission. (cIAI = complicated intra-abdominal infection).

system for a measure of SOI and ROM because pre-treatment measures such as APACHE II were not available.

Importantly, we noted substantial differences in the range of diseases treated, demographics, and the outcomes as compared with recently performed randomized registration trials [15–19]. These registration trials included younger patients (mean age <50 y) with complicated appendicitis as the most common infection. In addition, patients were not considered severely ill (APACHE II score predominantly ≤ 10) [15–17,19].

A key finding of this study was the similar outcomes in both treatment groups in the propensity-matched population and among those considered quite ill. Treatment success was not influenced by site of infection. The analysis of observational data sets matched based on a propensity score in this study overcomes potential bias induced by disease severity and treatment decision factors (as in Table 1A). When we compared outcomes between tigecycline and imipenem-cilastatin use, results were similar to those observed in the larger propensity score-matched patient population.

Few data are available examining post-discharge outcomes for patients with cIAI. Patients with cIAI typically are considered as a subset of patients with sepsis. Our data provide important insight into outcomes for patients with cIAI. Only

~25% of all patients were discharged home to self-care. An additional ~20% were discharged home but required professional health worker visits. Another 17% were transferred either to skilled nursing facilities or to other rehab facilities. All-cause re-hospitalization was increased in patients with treatment failure; however, no difference was reported in cIAI-related re-hospitalization between patients who had treatment failure and those with treatment success.

In contrast to our population, long-term outcomes in patients diagnosed with sepsis have been well documented. A systematic review by Winters et al. [20] reported on the long-term mortality rates in patients who had a diagnosis of sepsis or septic shock in 26 studies. Mortality rates after discharge at 1 y ranged from 7% to 43%. In the observational studies included in this review, mortality rates at 3 m to 6 m and 1 y ranged from 3% to 12% and 11% to 42.5%, respectively. The long-term patient outcomes reported in the current study are consistent with reports of patients with sepsis.

The large, multi-center nature of this study using a large healthcare database bolsters the generalizability of the data and study findings. The patients included in our analysis were more severely ill than those typically enrolled in phase 3 clinical trials and are more reflective of patients encountered in standard clinical practice. Use of propensity score

TABLE 4. TREATMENT SUCCESS TIGECYCLINE VERSUS IMPENEM-CILASTATIN

	Tigecycline (n=614) n/N (%)	Imipenem-cilastatin (n=699) n/N (%)	p
APR-DRG severity of illness ^a			
Mild (1)	1/ 1 (100.0)	1/ 1 (100.0)	1.000
Moderate (2)	60/ 63 (95.2)	53/ 59 (89.8)	0.2535
Major (3)	151/177 (85.3)	153/172 (89.0)	0.3100
Extreme (4)	217/373 (58.2)	272/467 (58.2)	0.9844
APR-DRG risk of death ^a			
Mild (1)	21/ 22 (95.5)	19/ 20 (95.0)	0.9449
Moderate (2)	102/114 (89.5)	99/114 (86.8)	0.5386
Major (3)	140/168 (83.3)	147/180 (81.7)	0.6828
Extreme (4)	166/310 (53.5)	214/385 (55.6)	0.5920
Vasopressor use	138/254 (54.3)	176/318 (55.3)	0.8084
Mechanical ventilator use	139/258 (53.9)	181/328 (55.2)	0.7524

^aAlgorithm-based and takes into consideration ICD-9 diagnosis, age, gender, discharge data, and d on mechanical ventilation.

APR-DRG = 3M™ All Patient Refined™ Diagnosis Related Group.

matching to evaluate the antibiotic therapies in similar patient groups strengthens our findings. The propensity score provided a way to more accurately match patients who had received tigecycline with those who received other agents, in addition to reducing the bias introduced by non-randomized treatment. The unmatched populations showed several differences, including greater SOI and ROM for the tigecycline-treated patients, and substantially more frequent use of ventilator and vasopressor support. These factors were adjusted by the propensity score matching. Once matching was used and differences between the treatment populations were accounted for, outcome results demonstrated similar success and failure rates across all SOI and ROM ranges. These results suggest that the treatments were similarly effective.

There are important limitations to this study. Firstly, the patients were not randomized to the treatments they received. Although the propensity score accounts for known and observed determinants of outcome, there may well be other unknown risk factors that lead physicians to use one agent versus another. Additionally, a major predictor of treatment failure in patients with cIAI is the timeliness and adequacy of source control. We were not able to evaluate these factors in our study. We cannot comment on the appropriateness in the individual case of tigecycline use. Finally, the data source limitations (e.g., lack of source controls and post-discharge information) only permit an evaluation of short- and long-term real-world outcomes in a large population of relatively sick patients with cIAI.

Conclusions

With propensity score matching to balance risk of treatment failure, tigecycline-treated patients with diagnosis of cIAI, in our model, were similar to patient populations treated for cIAI with other antimicrobial regimens. Although not propensity score-matched, tigecycline- and imipenem-cilastatin-treated patients were similar enough to allow us to compare outcomes. As with the matched comparison, our data suggest that in patients with more severe cIAI, similar outcomes are also achieved with tigecycline and imipenem-cilastatin treatment.

These data highlight the association between severity of acute illness and outcomes. Using propensity scores to match populations, similar outcomes were demonstrated between treatment with tigecycline and other antibiotics, as expressed by treatment success, similar 30-d discharge status, and the need for re-admission at 180 d.

Acknowledgments

This study was funded by Pfizer Inc. Mingfang Zhao, a former employee of the Premier, Inc., contributed to the study design and data analysis. Medical writing support was provided by Charlotte Kenreigh of Engage Scientific Solutions and funded by Pfizer Inc.

Author Disclosure Statement

Drs. Solomkin, Mullins, and Eckmann received remuneration from Pfizer Inc. for their services as members of the Steering Committee for the Tygacil® Observational Study. Dr. Mullins received grant funding from Bayer and Pfizer Inc., and consulting income from Bayer, BMS, Mundi Pharma, Novartis, and Pfizer Inc. At the time of the study, Drs. Ernst

and Krukus were full-time employees of the Premier, Inc., which has received financial support from Pfizer Inc. in connection with the study. Dr. Ernst is an employee of Indegene Inc. Dr. Krukus is an employee of Quintiles Inc. Drs. Quintana, Shalbaya, and Reisman are employees of Pfizer Inc.

References

1. Politano AD, Hranjec T, Rosenberger LH, et al. Differences in morbidity and mortality with percutaneous versus open surgical drainage of postoperative intra-abdominal infections: A review of 686 cases. *Am Surg* 2011;77:862–867.
2. Solomkin JS. Evaluating evidence and grading recommendations: The SIS/IDSA guidelines for the treatment of complicated intra-abdominal infections. *Surg Infect* 2010; 11:269–274.
3. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50:133–164.
4. Tygacil [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.;2014.
5. Eckmann C, Montravers P, Bassetti M, et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. *J Antimicrob Chemother* 2013;68:ii25–35.
6. Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections worldwide: The definitive data of the CIAOW Study. *World J Emerg Surg* 2014;9:37.
7. Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections in a worldwide context: An observational prospective study (CIAOW Study). *World J Emerg Surg* 2013;8:1.
8. Dick A, Liu H, Zwanziger J, et al. Long-term survival and healthcare utilization outcomes attributable to sepsis and pneumonia. *BMC Health Serv Res* 2012;12:432.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J Chronic Dis* 1987;40:373–383.
10. 3M™ APR-DRG Software. Available at: www.solutions.3m.com/wps/portal/3M/en_US/Health-Information-Systems/HIS/Products-and-Services/Products-List-A-Z/APR-DRG-Software/. Accessed January 16, 2015.
11. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. *Biometrika* 1983;70:41–55.
12. Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. *J Amer Statistic Assoc* 1984;79:516–524.
13. Gu X, Rosenbaum P. Comparison of multivariate matching methods: Structures, distances, and algorithms. *J Comput Graph Stat* 1993;2:405–420.
14. Stürmer T, Wyss R, Glynn R, Brookhart M. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. *J Intern Med* 2014;275:570–580.
15. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. *Clin Infect Dis* 2005;41:S354–367.
16. Namias N, Solomkin JS, Jensen EH, et al. Randomized, multicenter, double-blind study of efficacy, safety, and

- tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. *Surg Infect* 2007;8:15–28.
17. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: Results of a double-blind, randomized comparative phase III trial. *Ann Surg* 2003; 237:235–245.
 18. Solomkin J, Zhao YP, Ma EL, et al. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. *Int J Antimicrob Agents* 2009; 34:439–445.
 19. Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, non-inferiority study. *Clin Ther* 2008;30:868–883.
 20. Winters BD, Eberlein M, Leung J, et al. Long-term mortality and quality of life in sepsis: A systematic review. *Crit Care Med* 2010;38:1276–1283.

Address correspondence to:

Dr. Joseph Solomkin

University of Cincinnati College of Medicine

231 Albert B. Sabin Way

Cincinnati, OH 45267-0558

E-mail: solomkjs@ucmail.uc.edu

APPENDIX TABLE 1. DIAGNOSIS AND PROCEDURE CODES INDICATIVE OF COMPLICATED INTRA-ABDOMINAL INFECTIONS

ICD-9-CM code	Description
Intra-abdominal infection diagnosis codes	
531.1x and 531.5x ^a	Gastric ulcer with perforation
531.2x and 531.6x ^a	Gastric ulcer with hemorrhage and perforation
532.1x and 532.5x ^a	Duodenal ulcer with perforation
532.2x and 532.6x ^a	Duodenal ulcer with hemorrhage and perforation
533.1x and 533.5x ^a	Peptic ulcer with perforation
533.2x and 533.6x ^a	Peptic ulcer with hemorrhage and perforation
534.1x and 534.5x ^a	Gastrojejunal ulcer with perforation
534.2x and 534.6x ^a	Gastrojejunal ulcer with hemorrhage and perforation
540.0	Acute appendicitis with generalized peritonitis
540.1	Acute appendicitis with peritoneal abscess
567.x	Peritonitis
569.5	Abscess of intestine
569.81	Fistula of the intestine, excluding rectum and anus
569.82	Ulceration of intestine
569.83	Perforation of intestine
572.0	Abscess of liver
575.4 with one of the following:	Acute cholecystitis
574.0	Calculus of gallbladder with acute cholecystitis
574.3	Calculus of bile duct with acute cholecystitis
574.6	Calculus of gallbladder and bile duct with acute cholecystitis
574.8	Calculus of gallbladder and bile duct with acute and chronic cholecystitis
575.0	Acute cholecystitis
Surgical procedure codes	
43.xx ^b	Incision and excision of stomach
44.xx ^c	Other operations on stomach
45.xx ^d	Incision, excision, and anastomosis of intestine
46.xx ^e	Other operations on intestine
47.xx ^f	Operations on the appendix
50.91	Percutaneous aspiration of the liver
51.xx ^g	Operations on the gallbladder and biliary tract
52.99	Operations on the pancreas
54.xx ^h	Other operations on abdominal region
54.12	Re-opening of recent laparotomy site

^aBoth codes in the combination are required to indicate the diagnosis specified.

^bCodes included 43.5, 43.6, 43.7, 43.81, 43.82, 43.89, 43.91, 43.99.

^cCodes included 44.00, 44.01, 44.02, 44.03, 44.29, 44.39, 44.5, 44.63.

^dCodes included 45.00, 45.01, 45.02, 45.03, 45.61, 45.62, 45.63, 45.71, 45.72, 45.73, 45.74, 45.75, 45.76, 45.79, 45.81, 45.82, 45.83.

^eCodes included 46.10, 46.11, 46.13, 46.20, 46.21, 46.23, 46.40, 46.41, 46.71, 46.72, 46.73, 46.74, 46.75, 46.76, 46.79, 46.93, 46.94.

^fCodes included 47.01, 47.09, 47.2, 47.91, 47.92, 47.99.

^gCodes included 51.21, 51.22, 51.23, 51.24, 51.41, 51.42, 51.43, 51.51.

^hCodes included 54.12, 54.61, 54.91.

ICD-9-CM=International Classification of Diseases, Ninth Revision, Clinical Modification.

APPENDIX TABLE 2. PROPENSITY SCORE VARIABLES

Demographics
Age
Gender
Primary payer
Provider region
Admission source
Hospital
Teaching status
No. of beds
Health status
APR-DRG severity of illness
APR-DRG risk of death
Charlson Comorbidity Index
Vasopressor use
Mechanical ventilator use
Comorbidities ^a
Ever in ICU ^b
Length of stay prior to the index date
Severe sepsis and septic shock

^aMyocardial infarction, congestive heart failure, chronic pulmonary diseases, diabetes mellitus or diabetes mellitus with complications, liver or renal diseases.

^bDuring admission date and discharge date.

APR-DRG = 3M™ All Patient Refined™ Diagnosis Related Group; ICU = intensive care unit.

APPENDIX TABLE 3. OTHER ANTIBIOTIC THERAPIES^a (N = 1,818)

	n
Ampicillin	22
Cefepime	117
Cefotaxime	22
Cefoxitin	141
Ceftazidime	36
Ceftriaxone	171
Ciprofloxacin	374
Clindamycin	93
Doripenem	149
Ertapenem	282
Gentamicin	151
Imipenem-cilastatin	134
Meropenem	126
Metronidazole	1,085
Moxifloxacin	70
Piperacillin-tazobactam	1,071
Ticarcillin-clavulanate	4
Tobramycin	45
Vancomycin	744

^aPatients received varying combinations of listed therapies.

APPENDIX TABLE 4. PATIENT CHARACTERISTICS IMIPENEM-CILASTATIN COMPARISON (NO PROPENSITY MATCHING)

Characteristic ^a	Tigecycline (n = 614)	Imipenem-cilastatin (n = 699)	p
Mean age (SD), y	62.4 (16.0)	62.1 (15.6)	0.6085
Female	346 (56.4)	354 (50.6)	0.0386
White	447 (72.8)	504 (72.1)	0.0059
APR-DRG severity of illness			
Minor (1)	1 (0.2)	1 (0.1)	0.1550
Moderate (2)	63 (10.3)	59 (8.4)	
Major (3)	177 (28.8)	172 (24.6)	
Extreme (4)	373 (60.7)	467 (66.8)	
APR-DRG risk of death			
Minor (1)	22 (3.6)	20 (2.9)	0.3745
Moderate (2)	114 (18.6)	114 (16.3)	
Major (3)	168 (27.4)	180 (25.8)	
Extreme (4)	310 (50.5)	385 (55.1)	
Site of infection			
Stomach	15 (2.4)	14 (2.0)	0.5882
Appendix	11 (1.8)	8 (1.1)	0.3273
Liver	3 (0.5)	6 (0.9)	0.4178
Small intestine	168 (27.4)	206 (29.5)	0.3982
Large intestine	261 (42.5)	294 (42.1)	0.8697
Pancreas	—	1 (0.1)	0.3485
Gallbladder	33 (5.4)	47 (6.7)	0.3078
Other abdominal surgery ^b	226 (36.8)	248 (35.5)	0.6170
Vasopressor use	254 (41.4)	318 (45.5)	0.1325
Mechanical ventilator use	258 (42.0)	328 (46.9)	0.0745

^an (%), except for age.

^bIncludes percutaneous abdominal drainage, reopening of recent laparotomy site, and reclosure of post-operative disruption of abdominal wall.

APR-DRG = 3M™ All Patient Refined™ Diagnosis Related Group; SD = standard deviation.